Literature DB >> 6460777

Determination of 13-cis-retinoic acid and its major metabolite, 4-oxo-13-cis-retinoic acid, in human blood by reversed-phase high-performance liquid chromatography.

F M Vane, J K Stoltenborg, C J Buggé.   

Abstract

A high-performance liquid chromatography (HPLC) method for the quantitation of 13-cis-retinoic acid (13-cis-RA) and its major metabolite, 4-oxo-13-cis-RA, in human blood has been developed. The method includes extraction of 1 ml of blood with diethyl ether at pH 6 and the analysis of the extract by reversed-phase HPLC with solvent programming and detection at 365 nm. The quantitation ranges for 13-cis-RA and 4-oxo-13-cis-RA are 10--2000 and 50--2000 ng/ml of blood, respectively. The method also provides estimates of the concentrations of all-trans-RA and 4-oxo-all-trans-RA. The mean intra- and inter-assay variabilities for all four compounds were 6% or less. The method separates 13-cis-RA and 4-oxo-13-cis-RA from 9-cis-RA, all-trans-RA, 4-oxo-all-trans-RA, and some other possible metabolites, such as hydroxy and epoxy retinoic acids. The method has been successfully applied to the analyses of over 1200 blood samples from four 13-cis-RA clinical studies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460777     DOI: 10.1016/s0378-4347(00)80400-4

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man.

Authors:  W A Colburn; F M Vane; H J Shorter
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Pharmacokinetics of isotretinoin during repetitive dosing to patients.

Authors:  R K Brazzell; F M Vane; C W Ehmann; W A Colburn
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Comparative distribution, pharmacokinetics and placental permeabilities of all-trans-retinoic acid, 13-cis-retinoic acid, all-trans-4-oxo-retinoic acid, retinyl acetate and 9-cis-retinal in hamsters.

Authors:  W B Howard; C C Willhite; S T Omaye; R P Sharma
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

4.  Pharmacokinetics, tissue distribution and placental permeability of tetrahydro-tetramethyl-naphthalenyl-propenyl benzoic acid (a retinoidal benzoic acid derivative) in hamsters.

Authors:  W B Howard; C C Willhite; R P Sharma; S T Omaye; A Hatori
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Apr-Jun       Impact factor: 2.441

Review 5.  Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

6.  Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats.

Authors:  L Massacesi; E Castigli; M Vergelli; J Olivotto; A L Abbamondi; F Sarlo; L Amaducci
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

7.  Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

Authors:  Navin Pinto; Steven G DuBois; Araz Marachelian; Scott J Diede; Agne Taraseviciute; Julia L Glade Bender; Denice Tsao-Wei; Susan G Groshen; Joel M Reid; Daphne A Haas-Kogan; C Patrick Reynolds; Min H Kang; Meredith S Irwin; Margaret E Macy; Judith G Villablanca; Katherine K Matthay; Julie R Park
Journal:  Pediatr Blood Cancer       Date:  2018-03-30       Impact factor: 3.167

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.